Merck KGaA · ISIN: DE0006599905 · EQS - adhoc news

Strong 2nd Quarter, Guidance raised

Darmstadt, July 26, 2024: Based on a very strong second quarter of 2024 with net sales of EUR 5.352 bn resulting in an EBITDA pre1 of EUR 1.509 bn and an EPS pre1 of EUR 2.20, Merck KGaA (the "Company") has further raised its forecast for the entire group for fiscal 2024.  The main driver is a very strong operating performance of Healthcare and Electronics compared to consensus. The performance of Life Science is within expectations. The strong operating performance of Healthcare more than offse...

XETR:MRK Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Merck KGaA

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (6)
Short Selling (DE) (4)
Short Selling (UK) (0)
26 July 2024 06:50PM
Strong 2nd Quarter, Guidance raised
DE0006599905
Darmstadt, July 26, 2024: Based on a very strong second quarter of 2024 with net sales of EUR 5.352 bn resulting in an EBITDA pre1 of EUR 1.509 bn and an EPS pre1 of EUR 2.20, Merck KGaA (the "Company") has further raised its forecast for the entire group for fiscal 2024.  The main driver is a very strong operating performance of Healthcare and Ele...
Merck KGaA
About the publication
24 June 2024 07:00PM
Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
DE0006599905
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients ...
Merck KGaA
About the publication
24 June 2024 07:00PM
Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
DE0006599905
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients ...
Merck KGaA
About the publication
05 December 2023 09:34PM
Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide
DE0006599905
Darmstadt, 5 December 2023: Merck KGaA is investigating a highly selective oral and central nervous system penetrant Bruton’s tyrosine kinase inhibitor (BTKi) as a potential treatment for relapsing multiple sclerosis ("RMS") in two pivotal phase III clinical trials (evolutionRMS 1 and evolutionRMS 2, together the "Clinical Trials"). Both Clinical T...
Merck KGaA
About the publication
03 November 2021 06:42PM
Merck KGaA raises forecast for full year 2021
DE0006599905
Darmstadt, November 3, 2021. Based on a very strong third quarter of 2021 with net sales of EUR 4.97 bn resulting in EBITDA pre1 of EUR 1.55 bn and EPS pre1 of EUR 2.24, Merck KGaA (the "Company") has further raised its forecast for the entire group for fiscal 2021. The main driver is a very strong operating performance from the Life Science busine...
Merck KGaA
About the publication
04 May 2021 08:36PM
Merck KGaA raises forecast for full year 2021
DE0006599905
Darmstadt, 4 May 2021. Based on high demand expected to continue throughout the year and a very strong first quarter of 2021 with net sales of EUR 4.63 bn resulting in EBITDA pre1 of EUR 1.51 bn and EPS pre1 of EUR 2.18, Merck KGaA (the "Company") has raised its forecast for the entire group for fiscal 2021. The Company now projects net sales of ap...
Merck KGaA
About the publication
20 January 2021 01:30PM
Merck KGaA: Merck KGaA to discontinue bintrafusp alfa clinical trial (INTR@PID Lung 037)
DE0006599905
Merck KGaA (the "Company") is investigating a bifunctional immunotherapy, bintrafusp alfa (anti-PD-L1/TGF-beta trap), as a potential therapy for difficult to treat cancers. While reviewing the totality of data from the ongoing clinical trial INTR@PID Lung 037 in the first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) t...
Merck KGaA
About the publication
29 September 2020 06:06PM
Merck KGaA: Merck KGaA reverses provision for lawsuit in the amount of EUR 365 million
DE0006599905
Darmstadt, September 29, 2020. In the United States Merck KGaA's subsidiary EMD Serono, Inc. (Merck) is involved in a US patent dispute with Biogen Inc., United States (Biogen). Biogen sued Merck for damages in connection with a patent infringement caused by Merck's product Rebif before the U.S. District Court New Jersey, Newark. Merck defended its...
Merck KGaA
About the publication
More Merck KGaA related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 6 27th March 2024 Heinzel, Dr. Matthias DD
Short Seller (DE) 4 15th March 2024 Qube Research & Technologies Limited SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN